Malignant mesothelioma (MM) is a highly aggressive and lethal cancer with a poor survival
rate. Current treatment approaches primarily rely on chemotherapy and radiation, but their …

Cancer immunotherapy, exemplified by the remarkable clinical benefits of the immune
checkpoint blockade and chimeric antigen receptor T-cell therapy, is revolutionizing cancer …

MAPK pathway sparkles with RTK activation, passes through subsequent downstream RAS-
RAF-MEK-ERK signaling cascades, with consequent direct and indirect CDK4/6 signaling …

Abstract Macrophage-stimulating protein (MSP), a serum-derived growth factor belonging to
the plasminogen-related kringle domain family, is mainly produced by the liver and released …

Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with short survival
time. Unbalanced competing endogenous RNAs (ceRNAs) have been shown to participate …

Abstract The Cancer Genome Atlas (TCGA) of a pancreatic cancer cohort identified high
MST1R (RON tyrosine kinase receptor) expression correlated with poor prognosis in human …

The upregulated expression of tyrosine kinase AXL has been reported in several
hematologic and solid human tumors, including gastric, breast, colorectal, prostate and …

Simple Summary Why do most drugs have limited effects in difficult-to-treat cancers such as
mesothelioma? One explanation commonly given in response is that not enough drug can …

Abstract Background: RON (Recepteur d′ Origine Nantais) receptor tyrosine kinase is a
promising target for anti‐cancer therapeutics. The aim of this study was to identify new RON …

Endometriosis affects up to 10% of women of reproductive age, causing dysmenorrhea,
chronic pelvic pain, and infertility. The current key drug for endometriosis is dienogest, a …